nodes	percent_of_prediction	percent_of_DWPC	metapath
Alendronate—PTPN4—nephron tubule—kidney cancer	0.024	0.137	CbGeAlD
Alendronate—PTPRE—cardiac atrium—kidney cancer	0.0205	0.118	CbGeAlD
Alendronate—PTPN4—cortex of kidney—kidney cancer	0.0205	0.118	CbGeAlD
Alendronate—PTPRE—IL6-mediated signaling events—MITF—kidney cancer	0.0185	0.153	CbGpPWpGaD
Alendronate—FDPS—SREBP signalling—RNF139—kidney cancer	0.0143	0.119	CbGpPWpGaD
Alendronate—PTPRE—IL6-mediated signaling events—JUNB—kidney cancer	0.0133	0.11	CbGpPWpGaD
Alendronate—ATP6V1A—nephron tubule—kidney cancer	0.0119	0.0679	CbGeAlD
Alendronate—ATP6V1A—renal system—kidney cancer	0.0108	0.0617	CbGeAlD
Alendronate—ATP6V1A—kidney—kidney cancer	0.0104	0.0597	CbGeAlD
Alendronate—ATP6V1A—cortex of kidney—kidney cancer	0.0101	0.0581	CbGeAlD
Alendronate—ATP6V1A—gonad—kidney cancer	0.00966	0.0553	CbGeAlD
Alendronate—ATP6V1A—cardiac atrium—kidney cancer	0.00965	0.0553	CbGeAlD
Alendronate—FDPS—nephron tubule—kidney cancer	0.00893	0.0511	CbGeAlD
Alendronate—FDPS—renal system—kidney cancer	0.00812	0.0465	CbGeAlD
Alendronate—FDPS—kidney—kidney cancer	0.00785	0.0449	CbGeAlD
Alendronate—FDPS—cortex of kidney—kidney cancer	0.00764	0.0438	CbGeAlD
Alendronate—FDPS—gonad—kidney cancer	0.00728	0.0417	CbGeAlD
Alendronate—FDPS—cardiac atrium—kidney cancer	0.00727	0.0416	CbGeAlD
Alendronate—Zoledronate—CA2—kidney cancer	0.00553	0.521	CrCbGaD
Alendronate—PTPRE—IL6-mediated signaling events—JUN—kidney cancer	0.00521	0.0432	CbGpPWpGaD
Alendronate—PTPRE—IL6-mediated signaling events—MYC—kidney cancer	0.00419	0.0347	CbGpPWpGaD
Alendronate—PTPRE—IL6-mediated signaling events—PIK3CA—kidney cancer	0.00355	0.0294	CbGpPWpGaD
Alendronate—PTPRS—Extracellular matrix organization—BMP7—kidney cancer	0.00322	0.0267	CbGpPWpGaD
Alendronate—Risedronate—PTGS2—kidney cancer	0.00269	0.253	CrCbGaD
Alendronate—FDPS—SREBP signalling—SCARB1—kidney cancer	0.00251	0.0208	CbGpPWpGaD
Alendronate—Clodronate—PTGS2—kidney cancer	0.0024	0.226	CrCbGaD
Alendronate—PTPRS—Extracellular matrix organization—CTSB—kidney cancer	0.00221	0.0183	CbGpPWpGaD
Alendronate—PTPRS—Extracellular matrix organization—CTSD—kidney cancer	0.0022	0.0182	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling by Insulin receptor—EIF4EBP1—kidney cancer	0.00217	0.0179	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling by Insulin receptor—TSC1—kidney cancer	0.00201	0.0167	CbGpPWpGaD
Alendronate—ATP6V1A—Transmembrane transport of small molecules—RYR1—kidney cancer	0.00166	0.0137	CbGpPWpGaD
Alendronate—PTPRS—Extracellular matrix organization—KDR—kidney cancer	0.00119	0.00988	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling by Insulin receptor—TSC2—kidney cancer	0.00117	0.00972	CbGpPWpGaD
Alendronate—FDPS—Metabolism of lipids and lipoproteins—GLIPR1—kidney cancer	0.00106	0.00875	CbGpPWpGaD
Alendronate—PTPRS—Extracellular matrix organization—CDH1—kidney cancer	0.00101	0.00838	CbGpPWpGaD
Alendronate—FDPS—SREBP signalling—MTOR—kidney cancer	0.000962	0.00797	CbGpPWpGaD
Alendronate—ATP6V1A—Transmembrane transport of small molecules—ANXA2—kidney cancer	0.000952	0.00789	CbGpPWpGaD
Alendronate—ATP6V1A—Transmembrane transport of small molecules—SLC5A3—kidney cancer	0.000952	0.00789	CbGpPWpGaD
Alendronate—ATP6V1A—Transmembrane transport of small molecules—ATP7B—kidney cancer	0.000952	0.00789	CbGpPWpGaD
Alendronate—Influenza like illness—Doxorubicin—kidney cancer	0.000858	0.00124	CcSEcCtD
Alendronate—Vomiting—Pazopanib—kidney cancer	0.000855	0.00123	CcSEcCtD
Alendronate—Anaemia—Vincristine—kidney cancer	0.00085	0.00122	CcSEcCtD
Alendronate—Rash—Pazopanib—kidney cancer	0.000848	0.00122	CcSEcCtD
Alendronate—Nausea—Temsirolimus—kidney cancer	0.000848	0.00122	CcSEcCtD
Alendronate—Dermatitis—Pazopanib—kidney cancer	0.000847	0.00122	CcSEcCtD
Alendronate—Haemoglobin—Paclitaxel—kidney cancer	0.000843	0.00121	CcSEcCtD
Alendronate—Abdominal pain—Vinblastine—kidney cancer	0.000843	0.00121	CcSEcCtD
Alendronate—Headache—Pazopanib—kidney cancer	0.000843	0.00121	CcSEcCtD
Alendronate—Musculoskeletal discomfort—Sorafenib—kidney cancer	0.00084	0.00121	CcSEcCtD
Alendronate—Abdominal pain—Everolimus—kidney cancer	0.000839	0.00121	CcSEcCtD
Alendronate—Body temperature increased—Everolimus—kidney cancer	0.000839	0.00121	CcSEcCtD
Alendronate—Haemorrhage—Paclitaxel—kidney cancer	0.000839	0.00121	CcSEcCtD
Alendronate—Gastrointestinal pain—Erlotinib—kidney cancer	0.000838	0.00121	CcSEcCtD
Alendronate—Infection—Dactinomycin—kidney cancer	0.000834	0.0012	CcSEcCtD
Alendronate—Oedema peripheral—Paclitaxel—kidney cancer	0.000826	0.00119	CcSEcCtD
Alendronate—Vertigo—Vincristine—kidney cancer	0.000826	0.00119	CcSEcCtD
Alendronate—Abdominal discomfort—Capecitabine—kidney cancer	0.000824	0.00119	CcSEcCtD
Alendronate—ATP6V1A—Signaling by Insulin receptor—RAF1—kidney cancer	0.000813	0.00674	CbGpPWpGaD
Alendronate—Dyspepsia—Sorafenib—kidney cancer	0.000811	0.00117	CcSEcCtD
Alendronate—ATP6V1A—Disease—CCBL1—kidney cancer	0.00081	0.00671	CbGpPWpGaD
Alendronate—Abdominal pain—Erlotinib—kidney cancer	0.00081	0.00117	CcSEcCtD
Alendronate—Body temperature increased—Erlotinib—kidney cancer	0.00081	0.00117	CcSEcCtD
Alendronate—Ill-defined disorder—Gemcitabine—kidney cancer	0.000809	0.00117	CcSEcCtD
Alendronate—Musculoskeletal discomfort—Sunitinib—kidney cancer	0.000808	0.00116	CcSEcCtD
Alendronate—Oesophagitis—Doxorubicin—kidney cancer	0.000807	0.00116	CcSEcCtD
Alendronate—Anaemia—Gemcitabine—kidney cancer	0.000806	0.00116	CcSEcCtD
Alendronate—Nausea—Pazopanib—kidney cancer	0.000799	0.00115	CcSEcCtD
Alendronate—ATP6V1A—Signaling by Insulin receptor—MTOR—kidney cancer	0.000794	0.00658	CbGpPWpGaD
Alendronate—Erythema multiforme—Paclitaxel—kidney cancer	0.000793	0.00114	CcSEcCtD
Alendronate—Pain—Sorafenib—kidney cancer	0.000788	0.00114	CcSEcCtD
Alendronate—Constipation—Sorafenib—kidney cancer	0.000788	0.00114	CcSEcCtD
Alendronate—Malaise—Gemcitabine—kidney cancer	0.000786	0.00113	CcSEcCtD
Alendronate—Hypersensitivity—Vinblastine—kidney cancer	0.000785	0.00113	CcSEcCtD
Alendronate—Photosensitivity reaction—Capecitabine—kidney cancer	0.000785	0.00113	CcSEcCtD
Alendronate—Myalgia—Vincristine—kidney cancer	0.000783	0.00113	CcSEcCtD
Alendronate—Hypersensitivity—Everolimus—kidney cancer	0.000782	0.00113	CcSEcCtD
Alendronate—Dyspepsia—Sunitinib—kidney cancer	0.000781	0.00112	CcSEcCtD
Alendronate—Musculoskeletal discomfort—Dactinomycin—kidney cancer	0.000765	0.0011	CcSEcCtD
Alendronate—Asthenia—Vinblastine—kidney cancer	0.000765	0.0011	CcSEcCtD
Alendronate—Asthenia—Everolimus—kidney cancer	0.000762	0.0011	CcSEcCtD
Alendronate—Stevens-Johnson syndrome—Capecitabine—kidney cancer	0.00076	0.0011	CcSEcCtD
Alendronate—Pain—Sunitinib—kidney cancer	0.000758	0.00109	CcSEcCtD
Alendronate—Constipation—Sunitinib—kidney cancer	0.000758	0.00109	CcSEcCtD
Alendronate—Gastrointestinal pain—Sorafenib—kidney cancer	0.000754	0.00109	CcSEcCtD
Alendronate—Pruritus—Everolimus—kidney cancer	0.000751	0.00108	CcSEcCtD
Alendronate—Stomatitis—Capecitabine—kidney cancer	0.000747	0.00108	CcSEcCtD
Alendronate—Infection—Vincristine—kidney cancer	0.000745	0.00107	CcSEcCtD
Alendronate—Chest pain—Gemcitabine—kidney cancer	0.000742	0.00107	CcSEcCtD
Alendronate—Myalgia—Gemcitabine—kidney cancer	0.000742	0.00107	CcSEcCtD
Alendronate—Alopecia—Paclitaxel—kidney cancer	0.000741	0.00107	CcSEcCtD
Alendronate—Asthenia—Erlotinib—kidney cancer	0.000735	0.00106	CcSEcCtD
Alendronate—Discomfort—Gemcitabine—kidney cancer	0.000734	0.00106	CcSEcCtD
Alendronate—ATP6V1A—Disease—AMER1—kidney cancer	0.000733	0.00607	CbGpPWpGaD
Alendronate—Urticaria—Sorafenib—kidney cancer	0.000732	0.00106	CcSEcCtD
Alendronate—Photosensitivity—Doxorubicin—kidney cancer	0.00073	0.00105	CcSEcCtD
Alendronate—Erythema—Paclitaxel—kidney cancer	0.00073	0.00105	CcSEcCtD
Alendronate—Diarrhoea—Vinblastine—kidney cancer	0.000729	0.00105	CcSEcCtD
Alendronate—Abdominal pain—Sorafenib—kidney cancer	0.000729	0.00105	CcSEcCtD
Alendronate—Body temperature increased—Sorafenib—kidney cancer	0.000729	0.00105	CcSEcCtD
Alendronate—Diarrhoea—Everolimus—kidney cancer	0.000727	0.00105	CcSEcCtD
Alendronate—Gastrointestinal pain—Sunitinib—kidney cancer	0.000725	0.00105	CcSEcCtD
Alendronate—Pruritus—Erlotinib—kidney cancer	0.000725	0.00104	CcSEcCtD
Alendronate—Flatulence—Paclitaxel—kidney cancer	0.000719	0.00104	CcSEcCtD
Alendronate—Pain—Dactinomycin—kidney cancer	0.000718	0.00103	CcSEcCtD
Alendronate—Dysgeusia—Paclitaxel—kidney cancer	0.000715	0.00103	CcSEcCtD
Alendronate—ATP6V1A—Signaling Pathways—OR4C13—kidney cancer	0.00071	0.00588	CbGpPWpGaD
Alendronate—Infection—Gemcitabine—kidney cancer	0.000707	0.00102	CcSEcCtD
Alendronate—Dizziness—Vinblastine—kidney cancer	0.000705	0.00102	CcSEcCtD
Alendronate—Dizziness—Everolimus—kidney cancer	0.000702	0.00101	CcSEcCtD
Alendronate—Muscle spasms—Paclitaxel—kidney cancer	0.000702	0.00101	CcSEcCtD
Alendronate—Abdominal pain—Sunitinib—kidney cancer	0.000701	0.00101	CcSEcCtD
Alendronate—Body temperature increased—Sunitinib—kidney cancer	0.000701	0.00101	CcSEcCtD
Alendronate—Diarrhoea—Erlotinib—kidney cancer	0.000701	0.00101	CcSEcCtD
Alendronate—Feeling abnormal—Dactinomycin—kidney cancer	0.000692	0.000997	CcSEcCtD
Alendronate—Haemoglobin—Capecitabine—kidney cancer	0.000692	0.000997	CcSEcCtD
Alendronate—Haemorrhage—Capecitabine—kidney cancer	0.000688	0.000992	CcSEcCtD
Alendronate—Gastrointestinal pain—Dactinomycin—kidney cancer	0.000687	0.000989	CcSEcCtD
Alendronate—Musculoskeletal discomfort—Vincristine—kidney cancer	0.000684	0.000985	CcSEcCtD
Alendronate—Hypersensitivity—Sorafenib—kidney cancer	0.000679	0.000979	CcSEcCtD
Alendronate—FDPS—Metabolism—ACY1—kidney cancer	0.000679	0.00562	CbGpPWpGaD
Alendronate—Oedema peripheral—Capecitabine—kidney cancer	0.000678	0.000977	CcSEcCtD
Alendronate—Vomiting—Vinblastine—kidney cancer	0.000678	0.000977	CcSEcCtD
Alendronate—Dizziness—Erlotinib—kidney cancer	0.000678	0.000976	CcSEcCtD
Alendronate—Ill-defined disorder—Paclitaxel—kidney cancer	0.000677	0.000976	CcSEcCtD
Alendronate—Vomiting—Everolimus—kidney cancer	0.000675	0.000973	CcSEcCtD
Alendronate—Anaemia—Paclitaxel—kidney cancer	0.000675	0.000972	CcSEcCtD
Alendronate—Rash—Everolimus—kidney cancer	0.00067	0.000965	CcSEcCtD
Alendronate—Dermatitis—Everolimus—kidney cancer	0.000669	0.000964	CcSEcCtD
Alendronate—Headache—Vinblastine—kidney cancer	0.000668	0.000962	CcSEcCtD
Alendronate—Angioedema—Paclitaxel—kidney cancer	0.000667	0.000961	CcSEcCtD
Alendronate—Headache—Everolimus—kidney cancer	0.000665	0.000959	CcSEcCtD
Alendronate—Abdominal pain—Dactinomycin—kidney cancer	0.000664	0.000956	CcSEcCtD
Alendronate—Body temperature increased—Dactinomycin—kidney cancer	0.000664	0.000956	CcSEcCtD
Alendronate—Asthenia—Sorafenib—kidney cancer	0.000661	0.000953	CcSEcCtD
Alendronate—Malaise—Paclitaxel—kidney cancer	0.000658	0.000949	CcSEcCtD
Alendronate—Vertigo—Paclitaxel—kidney cancer	0.000656	0.000945	CcSEcCtD
Alendronate—Hypersensitivity—Sunitinib—kidney cancer	0.000653	0.000942	CcSEcCtD
Alendronate—Pruritus—Sorafenib—kidney cancer	0.000652	0.00094	CcSEcCtD
Alendronate—Vomiting—Erlotinib—kidney cancer	0.000651	0.000939	CcSEcCtD
Alendronate—Erythema multiforme—Capecitabine—kidney cancer	0.000651	0.000938	CcSEcCtD
Alendronate—Musculoskeletal discomfort—Gemcitabine—kidney cancer	0.000648	0.000934	CcSEcCtD
Alendronate—Rash—Erlotinib—kidney cancer	0.000646	0.000931	CcSEcCtD
Alendronate—Dermatitis—Erlotinib—kidney cancer	0.000645	0.00093	CcSEcCtD
Alendronate—Headache—Erlotinib—kidney cancer	0.000642	0.000925	CcSEcCtD
Alendronate—Pain—Vincristine—kidney cancer	0.000642	0.000924	CcSEcCtD
Alendronate—Constipation—Vincristine—kidney cancer	0.000642	0.000924	CcSEcCtD
Alendronate—Asthenia—Sunitinib—kidney cancer	0.000636	0.000917	CcSEcCtD
Alendronate—Nausea—Vinblastine—kidney cancer	0.000633	0.000912	CcSEcCtD
Alendronate—Nausea—Everolimus—kidney cancer	0.000631	0.000909	CcSEcCtD
Alendronate—Diarrhoea—Sorafenib—kidney cancer	0.000631	0.000909	CcSEcCtD
Alendronate—Pruritus—Sunitinib—kidney cancer	0.000628	0.000904	CcSEcCtD
Alendronate—Myalgia—Paclitaxel—kidney cancer	0.000622	0.000896	CcSEcCtD
Alendronate—Chest pain—Paclitaxel—kidney cancer	0.000622	0.000896	CcSEcCtD
Alendronate—Hypersensitivity—Dactinomycin—kidney cancer	0.000619	0.000891	CcSEcCtD
Alendronate—ATP6V1A—Disease—GPC3—kidney cancer	0.000614	0.00509	CbGpPWpGaD
Alendronate—Discomfort—Paclitaxel—kidney cancer	0.000614	0.000885	CcSEcCtD
Alendronate—Gastrointestinal pain—Vincristine—kidney cancer	0.000613	0.000884	CcSEcCtD
Alendronate—Dizziness—Sorafenib—kidney cancer	0.00061	0.000878	CcSEcCtD
Alendronate—Constipation—Gemcitabine—kidney cancer	0.000609	0.000877	CcSEcCtD
Alendronate—Pain—Gemcitabine—kidney cancer	0.000609	0.000877	CcSEcCtD
Alendronate—Nausea—Erlotinib—kidney cancer	0.000609	0.000877	CcSEcCtD
Alendronate—Alopecia—Capecitabine—kidney cancer	0.000608	0.000876	CcSEcCtD
Alendronate—Diarrhoea—Sunitinib—kidney cancer	0.000607	0.000874	CcSEcCtD
Alendronate—ATP6V1A—Signaling Pathways—LATS1—kidney cancer	0.000604	0.005	CbGpPWpGaD
Alendronate—Asthenia—Dactinomycin—kidney cancer	0.000602	0.000868	CcSEcCtD
Alendronate—Erythema—Capecitabine—kidney cancer	0.000599	0.000863	CcSEcCtD
Alendronate—Abdominal pain—Vincristine—kidney cancer	0.000593	0.000855	CcSEcCtD
Alendronate—Body temperature increased—Vincristine—kidney cancer	0.000593	0.000855	CcSEcCtD
Alendronate—Infection—Paclitaxel—kidney cancer	0.000592	0.000853	CcSEcCtD
Alendronate—Flatulence—Capecitabine—kidney cancer	0.00059	0.000851	CcSEcCtD
Alendronate—Dry skin—Doxorubicin—kidney cancer	0.000588	0.000847	CcSEcCtD
Alendronate—Dysgeusia—Capecitabine—kidney cancer	0.000587	0.000845	CcSEcCtD
Alendronate—Dizziness—Sunitinib—kidney cancer	0.000587	0.000845	CcSEcCtD
Alendronate—Feeling abnormal—Gemcitabine—kidney cancer	0.000586	0.000845	CcSEcCtD
Alendronate—FDPS—SREBP signalling—PIK3CA—kidney cancer	0.000586	0.00486	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling by Insulin receptor—MAPK3—kidney cancer	0.000586	0.00486	CbGpPWpGaD
Alendronate—Vomiting—Sorafenib—kidney cancer	0.000586	0.000844	CcSEcCtD
Alendronate—Rash—Sorafenib—kidney cancer	0.000581	0.000837	CcSEcCtD
Alendronate—Dermatitis—Sorafenib—kidney cancer	0.000581	0.000837	CcSEcCtD
Alendronate—FDPS—Metabolism of lipids and lipoproteins—CRABP1—kidney cancer	0.000579	0.00479	CbGpPWpGaD
Alendronate—Toxic epidermal necrolysis—Doxorubicin—kidney cancer	0.000578	0.000832	CcSEcCtD
Alendronate—Headache—Sorafenib—kidney cancer	0.000577	0.000832	CcSEcCtD
Alendronate—FDPS—Metabolism—PDHB—kidney cancer	0.000577	0.00478	CbGpPWpGaD
Alendronate—Muscle spasms—Capecitabine—kidney cancer	0.000576	0.00083	CcSEcCtD
Alendronate—Diarrhoea—Dactinomycin—kidney cancer	0.000575	0.000828	CcSEcCtD
Alendronate—ATP6V1A—Disease—ST3GAL2—kidney cancer	0.000568	0.00471	CbGpPWpGaD
Alendronate—Gastritis—Doxorubicin—kidney cancer	0.000568	0.000818	CcSEcCtD
Alendronate—Vomiting—Sunitinib—kidney cancer	0.000564	0.000813	CcSEcCtD
Alendronate—Body temperature increased—Gemcitabine—kidney cancer	0.000563	0.000811	CcSEcCtD
Alendronate—Rash—Sunitinib—kidney cancer	0.000559	0.000806	CcSEcCtD
Alendronate—Dermatitis—Sunitinib—kidney cancer	0.000559	0.000805	CcSEcCtD
Alendronate—Abdominal distension—Doxorubicin—kidney cancer	0.000558	0.000804	CcSEcCtD
Alendronate—ATP6V1A—Signaling by Insulin receptor—MAPK1—kidney cancer	0.000558	0.00462	CbGpPWpGaD
Alendronate—Ill-defined disorder—Capecitabine—kidney cancer	0.000556	0.000801	CcSEcCtD
Alendronate—Headache—Sunitinib—kidney cancer	0.000556	0.000801	CcSEcCtD
Alendronate—Asthma—Doxorubicin—kidney cancer	0.000554	0.000799	CcSEcCtD
Alendronate—Dysphagia—Doxorubicin—kidney cancer	0.000554	0.000799	CcSEcCtD
Alendronate—Anaemia—Capecitabine—kidney cancer	0.000554	0.000798	CcSEcCtD
Alendronate—Hypersensitivity—Vincristine—kidney cancer	0.000553	0.000796	CcSEcCtD
Alendronate—Nausea—Sorafenib—kidney cancer	0.000548	0.000789	CcSEcCtD
Alendronate—Musculoskeletal discomfort—Paclitaxel—kidney cancer	0.000543	0.000782	CcSEcCtD
Alendronate—FDPS—Metabolism—CCBL1—kidney cancer	0.000543	0.00449	CbGpPWpGaD
Alendronate—Malaise—Capecitabine—kidney cancer	0.00054	0.000779	CcSEcCtD
Alendronate—Vertigo—Capecitabine—kidney cancer	0.000538	0.000776	CcSEcCtD
Alendronate—Asthenia—Vincristine—kidney cancer	0.000538	0.000776	CcSEcCtD
Alendronate—Vomiting—Dactinomycin—kidney cancer	0.000534	0.000769	CcSEcCtD
Alendronate—ATP6V1A—Disease—PGK1—kidney cancer	0.000533	0.00441	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—SLC5A3—kidney cancer	0.000533	0.00441	CbGpPWpGaD
Alendronate—Rash—Dactinomycin—kidney cancer	0.000529	0.000763	CcSEcCtD
Alendronate—Nausea—Sunitinib—kidney cancer	0.000527	0.000759	CcSEcCtD
Alendronate—ATP6V1A—Signaling by Insulin receptor—KRAS—kidney cancer	0.000527	0.00436	CbGpPWpGaD
Alendronate—Dyspepsia—Paclitaxel—kidney cancer	0.000525	0.000756	CcSEcCtD
Alendronate—ATP6V1A—Disease—SFRP2—kidney cancer	0.000522	0.00433	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—LDHB—kidney cancer	0.000522	0.00433	CbGpPWpGaD
Alendronate—Diarrhoea—Vincristine—kidney cancer	0.000513	0.00074	CcSEcCtD
Alendronate—ATP6V1A—Signaling Pathways—AMER1—kidney cancer	0.000513	0.00425	CbGpPWpGaD
Alendronate—Asthenia—Gemcitabine—kidney cancer	0.000511	0.000736	CcSEcCtD
Alendronate—Myalgia—Capecitabine—kidney cancer	0.00051	0.000735	CcSEcCtD
Alendronate—Chest pain—Capecitabine—kidney cancer	0.00051	0.000735	CcSEcCtD
Alendronate—Constipation—Paclitaxel—kidney cancer	0.00051	0.000734	CcSEcCtD
Alendronate—Pain—Paclitaxel—kidney cancer	0.00051	0.000734	CcSEcCtD
Alendronate—Photosensitivity reaction—Doxorubicin—kidney cancer	0.000506	0.000729	CcSEcCtD
Alendronate—Discomfort—Capecitabine—kidney cancer	0.000504	0.000726	CcSEcCtD
Alendronate—Pruritus—Gemcitabine—kidney cancer	0.000504	0.000726	CcSEcCtD
Alendronate—ATP6V1A—Transmembrane transport of small molecules—SLC5A5—kidney cancer	0.000502	0.00416	CbGpPWpGaD
Alendronate—Nausea—Dactinomycin—kidney cancer	0.000499	0.000719	CcSEcCtD
Alendronate—Dizziness—Vincristine—kidney cancer	0.000496	0.000715	CcSEcCtD
Alendronate—Feeling abnormal—Paclitaxel—kidney cancer	0.000491	0.000708	CcSEcCtD
Alendronate—FDPS—Metabolism of lipids and lipoproteins—ACHE—kidney cancer	0.000491	0.00406	CbGpPWpGaD
Alendronate—Stevens-Johnson syndrome—Doxorubicin—kidney cancer	0.00049	0.000706	CcSEcCtD
Alendronate—Gastrointestinal pain—Paclitaxel—kidney cancer	0.000487	0.000702	CcSEcCtD
Alendronate—ATP6V1A—Disease—TCEB1—kidney cancer	0.000487	0.00403	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—TCEB2—kidney cancer	0.000487	0.00403	CbGpPWpGaD
Alendronate—Diarrhoea—Gemcitabine—kidney cancer	0.000487	0.000702	CcSEcCtD
Alendronate—Infection—Capecitabine—kidney cancer	0.000486	0.0007	CcSEcCtD
Alendronate—ATP6V1A—Transmembrane transport of small molecules—SLC2A1—kidney cancer	0.000485	0.00402	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling by Insulin receptor—PIK3CA—kidney cancer	0.000484	0.00401	CbGpPWpGaD
Alendronate—Stomatitis—Doxorubicin—kidney cancer	0.000482	0.000694	CcSEcCtD
Alendronate—Vomiting—Vincristine—kidney cancer	0.000477	0.000687	CcSEcCtD
Alendronate—Urticaria—Paclitaxel—kidney cancer	0.000473	0.000682	CcSEcCtD
Alendronate—Rash—Vincristine—kidney cancer	0.000473	0.000682	CcSEcCtD
Alendronate—Dermatitis—Vincristine—kidney cancer	0.000473	0.000681	CcSEcCtD
Alendronate—Body temperature increased—Paclitaxel—kidney cancer	0.000471	0.000679	CcSEcCtD
Alendronate—Abdominal pain—Paclitaxel—kidney cancer	0.000471	0.000679	CcSEcCtD
Alendronate—FDPS—Metabolism—PPAT—kidney cancer	0.00047	0.0039	CbGpPWpGaD
Alendronate—FDPS—Metabolism—GLIPR1—kidney cancer	0.00047	0.0039	CbGpPWpGaD
Alendronate—Headache—Vincristine—kidney cancer	0.00047	0.000677	CcSEcCtD
Alendronate—FDPS—Metabolism of lipids and lipoproteins—SCARB1—kidney cancer	0.000464	0.00385	CbGpPWpGaD
Alendronate—FDPS—Metabolism of lipids and lipoproteins—PTGS1—kidney cancer	0.00046	0.00381	CbGpPWpGaD
Alendronate—Vomiting—Gemcitabine—kidney cancer	0.000453	0.000652	CcSEcCtD
Alendronate—Rash—Gemcitabine—kidney cancer	0.000449	0.000647	CcSEcCtD
Alendronate—Dermatitis—Gemcitabine—kidney cancer	0.000448	0.000646	CcSEcCtD
Alendronate—Haemoglobin—Doxorubicin—kidney cancer	0.000446	0.000643	CcSEcCtD
Alendronate—Headache—Gemcitabine—kidney cancer	0.000446	0.000642	CcSEcCtD
Alendronate—Nausea—Vincristine—kidney cancer	0.000446	0.000642	CcSEcCtD
Alendronate—Musculoskeletal discomfort—Capecitabine—kidney cancer	0.000446	0.000642	CcSEcCtD
Alendronate—Haemorrhage—Doxorubicin—kidney cancer	0.000444	0.000639	CcSEcCtD
Alendronate—Hypersensitivity—Paclitaxel—kidney cancer	0.000439	0.000633	CcSEcCtD
Alendronate—FDPS—Metabolism—FH—kidney cancer	0.000437	0.00362	CbGpPWpGaD
Alendronate—FDPS—Metabolism—APRT—kidney cancer	0.000437	0.00362	CbGpPWpGaD
Alendronate—Oedema peripheral—Doxorubicin—kidney cancer	0.000437	0.00063	CcSEcCtD
Alendronate—Dyspepsia—Capecitabine—kidney cancer	0.00043	0.00062	CcSEcCtD
Alendronate—ATP6V1A—Signaling Pathways—CER1—kidney cancer	0.00043	0.00356	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—GPC3—kidney cancer	0.00043	0.00356	CbGpPWpGaD
Alendronate—Asthenia—Paclitaxel—kidney cancer	0.000428	0.000616	CcSEcCtD
Alendronate—FDPS—Metabolism of lipids and lipoproteins—BCHE—kidney cancer	0.000427	0.00354	CbGpPWpGaD
Alendronate—Nausea—Gemcitabine—kidney cancer	0.000423	0.000609	CcSEcCtD
Alendronate—Pruritus—Paclitaxel—kidney cancer	0.000422	0.000607	CcSEcCtD
Alendronate—Erythema multiforme—Doxorubicin—kidney cancer	0.000419	0.000604	CcSEcCtD
Alendronate—Pain—Capecitabine—kidney cancer	0.000418	0.000603	CcSEcCtD
Alendronate—Constipation—Capecitabine—kidney cancer	0.000418	0.000603	CcSEcCtD
Alendronate—FDPS—Metabolism—GPC3—kidney cancer	0.000411	0.00341	CbGpPWpGaD
Alendronate—Diarrhoea—Paclitaxel—kidney cancer	0.000408	0.000587	CcSEcCtD
Alendronate—Feeling abnormal—Capecitabine—kidney cancer	0.000403	0.000581	CcSEcCtD
Alendronate—FDPS—Metabolism—CA2—kidney cancer	0.0004	0.00331	CbGpPWpGaD
Alendronate—Gastrointestinal pain—Capecitabine—kidney cancer	0.0004	0.000576	CcSEcCtD
Alendronate—ATP6V1A—Disease—RPL14—kidney cancer	0.000396	0.00328	CbGpPWpGaD
Alendronate—Dizziness—Paclitaxel—kidney cancer	0.000394	0.000568	CcSEcCtD
Alendronate—Alopecia—Doxorubicin—kidney cancer	0.000392	0.000565	CcSEcCtD
Alendronate—FDPS—Metabolism—ALAD—kidney cancer	0.00039	0.00323	CbGpPWpGaD
Alendronate—Urticaria—Capecitabine—kidney cancer	0.000388	0.00056	CcSEcCtD
Alendronate—Body temperature increased—Capecitabine—kidney cancer	0.000387	0.000557	CcSEcCtD
Alendronate—Abdominal pain—Capecitabine—kidney cancer	0.000387	0.000557	CcSEcCtD
Alendronate—Erythema—Doxorubicin—kidney cancer	0.000386	0.000556	CcSEcCtD
Alendronate—ATP6V1A—Transmembrane transport of small molecules—ABCB1—kidney cancer	0.000383	0.00317	CbGpPWpGaD
Alendronate—Flatulence—Doxorubicin—kidney cancer	0.000381	0.000548	CcSEcCtD
Alendronate—FDPS—Metabolism—ST3GAL2—kidney cancer	0.00038	0.00315	CbGpPWpGaD
Alendronate—Vomiting—Paclitaxel—kidney cancer	0.000379	0.000546	CcSEcCtD
Alendronate—Dysgeusia—Doxorubicin—kidney cancer	0.000378	0.000545	CcSEcCtD
Alendronate—Rash—Paclitaxel—kidney cancer	0.000376	0.000541	CcSEcCtD
Alendronate—Dermatitis—Paclitaxel—kidney cancer	0.000375	0.000541	CcSEcCtD
Alendronate—Headache—Paclitaxel—kidney cancer	0.000373	0.000538	CcSEcCtD
Alendronate—FDPS—Metabolism—ALDH1A1—kidney cancer	0.000372	0.00308	CbGpPWpGaD
Alendronate—Muscle spasms—Doxorubicin—kidney cancer	0.000371	0.000535	CcSEcCtD
Alendronate—ATP6V1A—Signaling Pathways—SFRP2—kidney cancer	0.000366	0.00303	CbGpPWpGaD
Alendronate—Hypersensitivity—Capecitabine—kidney cancer	0.00036	0.000519	CcSEcCtD
Alendronate—Ill-defined disorder—Doxorubicin—kidney cancer	0.000358	0.000516	CcSEcCtD
Alendronate—ATP6V1A—Disease—ITPR2—kidney cancer	0.000358	0.00297	CbGpPWpGaD
Alendronate—Anaemia—Doxorubicin—kidney cancer	0.000357	0.000514	CcSEcCtD
Alendronate—FDPS—Metabolism—SLC5A3—kidney cancer	0.000357	0.00295	CbGpPWpGaD
Alendronate—FDPS—Metabolism—PGK1—kidney cancer	0.000357	0.00295	CbGpPWpGaD
Alendronate—Nausea—Paclitaxel—kidney cancer	0.000354	0.00051	CcSEcCtD
Alendronate—Asthenia—Capecitabine—kidney cancer	0.000351	0.000506	CcSEcCtD
Alendronate—FDPS—Metabolism—LDHB—kidney cancer	0.00035	0.0029	CbGpPWpGaD
Alendronate—Malaise—Doxorubicin—kidney cancer	0.000348	0.000502	CcSEcCtD
Alendronate—Vertigo—Doxorubicin—kidney cancer	0.000347	0.0005	CcSEcCtD
Alendronate—Pruritus—Capecitabine—kidney cancer	0.000346	0.000498	CcSEcCtD
Alendronate—Diarrhoea—Capecitabine—kidney cancer	0.000335	0.000482	CcSEcCtD
Alendronate—Chest pain—Doxorubicin—kidney cancer	0.000329	0.000474	CcSEcCtD
Alendronate—Myalgia—Doxorubicin—kidney cancer	0.000329	0.000474	CcSEcCtD
Alendronate—Discomfort—Doxorubicin—kidney cancer	0.000325	0.000468	CcSEcCtD
Alendronate—Dizziness—Capecitabine—kidney cancer	0.000323	0.000466	CcSEcCtD
Alendronate—Infection—Doxorubicin—kidney cancer	0.000313	0.000451	CcSEcCtD
Alendronate—Vomiting—Capecitabine—kidney cancer	0.000311	0.000448	CcSEcCtD
Alendronate—Rash—Capecitabine—kidney cancer	0.000308	0.000444	CcSEcCtD
Alendronate—Dermatitis—Capecitabine—kidney cancer	0.000308	0.000444	CcSEcCtD
Alendronate—Headache—Capecitabine—kidney cancer	0.000306	0.000441	CcSEcCtD
Alendronate—FDPS—Metabolism—CA9—kidney cancer	0.000303	0.00251	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—PSMD7—kidney cancer	0.0003	0.00248	CbGpPWpGaD
Alendronate—FDPS—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	0.000296	0.00245	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—AKAP13—kidney cancer	0.000295	0.00244	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—CASP2—kidney cancer	0.000295	0.00244	CbGpPWpGaD
Alendronate—Nausea—Capecitabine—kidney cancer	0.00029	0.000419	CcSEcCtD
Alendronate—Musculoskeletal discomfort—Doxorubicin—kidney cancer	0.000287	0.000414	CcSEcCtD
Alendronate—Dyspepsia—Doxorubicin—kidney cancer	0.000277	0.0004	CcSEcCtD
Alendronate—ATP6V1A—Disease—SLC2A1—kidney cancer	0.000271	0.00225	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—GRB7—kidney cancer	0.00027	0.00223	CbGpPWpGaD
Alendronate—Constipation—Doxorubicin—kidney cancer	0.00027	0.000388	CcSEcCtD
Alendronate—Pain—Doxorubicin—kidney cancer	0.00027	0.000388	CcSEcCtD
Alendronate—ATP6V1A—Disease—JUNB—kidney cancer	0.000269	0.00223	CbGpPWpGaD
Alendronate—Feeling abnormal—Doxorubicin—kidney cancer	0.00026	0.000374	CcSEcCtD
Alendronate—FDPS—Metabolism—CRABP1—kidney cancer	0.000258	0.00214	CbGpPWpGaD
Alendronate—Gastrointestinal pain—Doxorubicin—kidney cancer	0.000258	0.000371	CcSEcCtD
Alendronate—ATP6V1A—Signaling Pathways—ITPR2—kidney cancer	0.000251	0.00208	CbGpPWpGaD
Alendronate—Urticaria—Doxorubicin—kidney cancer	0.00025	0.000361	CcSEcCtD
Alendronate—Body temperature increased—Doxorubicin—kidney cancer	0.000249	0.000359	CcSEcCtD
Alendronate—Abdominal pain—Doxorubicin—kidney cancer	0.000249	0.000359	CcSEcCtD
Alendronate—FDPS—Metabolism—ITPR2—kidney cancer	0.00024	0.00199	CbGpPWpGaD
Alendronate—Hypersensitivity—Doxorubicin—kidney cancer	0.000232	0.000335	CcSEcCtD
Alendronate—ATP6V1A—Signaling Pathways—CTNNA1—kidney cancer	0.000227	0.00188	CbGpPWpGaD
Alendronate—Asthenia—Doxorubicin—kidney cancer	0.000226	0.000326	CcSEcCtD
Alendronate—ATP6V1A—Signaling Pathways—EIF4EBP1—kidney cancer	0.000226	0.00187	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—HSPB1—kidney cancer	0.000226	0.00187	CbGpPWpGaD
Alendronate—Pruritus—Doxorubicin—kidney cancer	0.000223	0.000321	CcSEcCtD
Alendronate—FDPS—Metabolism of lipids and lipoproteins—POMC—kidney cancer	0.000221	0.00183	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—CDKN2B—kidney cancer	0.000219	0.00182	CbGpPWpGaD
Alendronate—FDPS—Metabolism—ACHE—kidney cancer	0.000219	0.00181	CbGpPWpGaD
Alendronate—FDPS—Metabolism—GSTT1—kidney cancer	0.000219	0.00181	CbGpPWpGaD
Alendronate—ATP6V1A—Transmembrane transport of small molecules—RAF1—kidney cancer	0.000217	0.00179	CbGpPWpGaD
Alendronate—Diarrhoea—Doxorubicin—kidney cancer	0.000216	0.000311	CcSEcCtD
Alendronate—ATP6V1A—Signaling Pathways—PSMD7—kidney cancer	0.00021	0.00174	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—ANXA1—kidney cancer	0.00021	0.00174	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—TSC1—kidney cancer	0.00021	0.00174	CbGpPWpGaD
Alendronate—Dizziness—Doxorubicin—kidney cancer	0.000208	0.0003	CcSEcCtD
Alendronate—FDPS—Metabolism—SCARB1—kidney cancer	0.000207	0.00171	CbGpPWpGaD
Alendronate—FDPS—Metabolism—PTGS1—kidney cancer	0.000205	0.0017	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—FLT1—kidney cancer	0.000203	0.00169	CbGpPWpGaD
Alendronate—FDPS—Metabolism—PSMD7—kidney cancer	0.000201	0.00166	CbGpPWpGaD
Alendronate—Vomiting—Doxorubicin—kidney cancer	0.0002	0.000289	CcSEcCtD
Alendronate—Rash—Doxorubicin—kidney cancer	0.000199	0.000286	CcSEcCtD
Alendronate—Dermatitis—Doxorubicin—kidney cancer	0.000199	0.000286	CcSEcCtD
Alendronate—Headache—Doxorubicin—kidney cancer	0.000197	0.000285	CcSEcCtD
Alendronate—FDPS—Metabolism—BCHE—kidney cancer	0.00019	0.00158	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—PAK1—kidney cancer	0.000189	0.00156	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—JUNB—kidney cancer	0.000189	0.00156	CbGpPWpGaD
Alendronate—FDPS—Metabolism—SLC5A5—kidney cancer	0.000188	0.00156	CbGpPWpGaD
Alendronate—Nausea—Doxorubicin—kidney cancer	0.000187	0.00027	CcSEcCtD
Alendronate—FDPS—Metabolism—SLC2A1—kidney cancer	0.000182	0.0015	CbGpPWpGaD
Alendronate—FDPS—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	0.000176	0.00146	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—HIF1A—kidney cancer	0.000175	0.00145	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—TSC2—kidney cancer	0.000175	0.00145	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—APC—kidney cancer	0.000154	0.00128	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—KIT—kidney cancer	0.000154	0.00128	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—IGF2—kidney cancer	0.000154	0.00128	CbGpPWpGaD
Alendronate—FDPS—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	0.000154	0.00127	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—CDKN2B—kidney cancer	0.000153	0.00127	CbGpPWpGaD
Alendronate—FDPS—Metabolism—GSTP1—kidney cancer	0.000151	0.00125	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—IGF1R—kidney cancer	0.000149	0.00123	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—BRAF—kidney cancer	0.000145	0.0012	CbGpPWpGaD
Alendronate—FDPS—Metabolism—ABCB1—kidney cancer	0.000143	0.00119	CbGpPWpGaD
Alendronate—FDPS—Metabolism—GSTM1—kidney cancer	0.000139	0.00115	CbGpPWpGaD
Alendronate—FDPS—Metabolism—CYP1A1—kidney cancer	0.000132	0.00109	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—HIF1A—kidney cancer	0.000123	0.00102	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—TSC2—kidney cancer	0.000122	0.00101	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—RAF1—kidney cancer	0.000121	0.001	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—ERBB2—kidney cancer	0.00012	0.000993	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—MTOR—kidney cancer	0.000118	0.00098	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—CD4—kidney cancer	0.000118	0.000978	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—KDR—kidney cancer	0.000117	0.000972	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—PTGS2—kidney cancer	0.000117	0.000971	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—CDKN1B—kidney cancer	0.000111	0.00092	CbGpPWpGaD
Alendronate—FDPS—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	0.000108	0.000898	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—KIT—kidney cancer	0.000108	0.000896	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—APC—kidney cancer	0.000108	0.000896	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—CTNNB1—kidney cancer	0.000105	0.000869	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—POMC—kidney cancer	0.000103	0.000852	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—PTEN—kidney cancer	0.000102	0.000847	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—BRAF—kidney cancer	0.000102	0.000842	CbGpPWpGaD
Alendronate—FDPS—Metabolism—POMC—kidney cancer	9.84e-05	0.000815	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—MAPK3—kidney cancer	8.73e-05	0.000724	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—MYC—kidney cancer	8.49e-05	0.000704	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—RAF1—kidney cancer	8.48e-05	0.000703	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—RELA—kidney cancer	8.45e-05	0.0007	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—ERBB2—kidney cancer	8.39e-05	0.000695	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—MAPK1—kidney cancer	8.31e-05	0.000688	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—MTOR—kidney cancer	8.28e-05	0.000686	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—KRAS—kidney cancer	7.85e-05	0.00065	CbGpPWpGaD
Alendronate—FDPS—Metabolism—PTGS2—kidney cancer	7.85e-05	0.00065	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—CDKN1B—kidney cancer	7.77e-05	0.000644	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—IL2—kidney cancer	7.61e-05	0.00063	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—CCND1—kidney cancer	7.42e-05	0.000614	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—JUN—kidney cancer	7.4e-05	0.000613	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—CTNNB1—kidney cancer	7.34e-05	0.000608	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—PIK3CA—kidney cancer	7.21e-05	0.000597	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—PTEN—kidney cancer	7.16e-05	0.000593	CbGpPWpGaD
Alendronate—FDPS—Metabolism—PTEN—kidney cancer	6.84e-05	0.000567	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—VEGFA—kidney cancer	6.47e-05	0.000536	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—MAPK3—kidney cancer	6.12e-05	0.000507	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—MYC—kidney cancer	5.95e-05	0.000493	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—MAPK1—kidney cancer	5.82e-05	0.000482	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—KRAS—kidney cancer	5.5e-05	0.000455	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—PIK3CA—kidney cancer	5.05e-05	0.000418	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—TP53—kidney cancer	4.89e-05	0.000405	CbGpPWpGaD
Alendronate—FDPS—Metabolism—PIK3CA—kidney cancer	4.83e-05	0.0004	CbGpPWpGaD
